The Cubist Story

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.

Building a Pipeline with Purpose

Acute care is the space where we work and invest. In the U.S., Cubist markets CUBICIN^® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and ENTEREG^® (alvimopan), the first and only FDA-approved therapy to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Cubist also has an agreement with Optimer Pharmaceuticals, Inc. to co-promote Optimer's drug, DIFICID^™ (fidaxomicin), in the U.S. as a treatment of Clostridium difficile-associated diarrhea (CDAD). Cubist's clinical product pipeline currently consists of a Phase 3 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms. Also, the company is planning on initiating a Phase 3 program for the treatment of CDAD in the first half of 2012. In addition, the company has an oral, peripherally-restricted opioid receptor antagonist in development for the treatment of chronic opioid induced constipation (OIC) and expects to begin Phase 3 studies in 2012. Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain.

Cubist is headquartered in Lexington, MA and employs approximately 700 people. The company's FY11 total net revenues increased 18% to $754 million as compared to FY10.

History

Founded in 1992, Cubist has maintained its focus on becoming a leader in the discovery, development and commercialization of novel acute care therapies for use in hospitals and other acute care environments.

Cubist completed its initial public offering (IPO) in 1996, and its shares are listed on NASDAQ (ticker symbol: CBST). In 1997, at a time when most pharmaceutical companies had abandoned discovery and development of antibiotics, Cubist in-licensed daptomycin, a first-in-class cyclic lipopeptide antibiotic drug candidate, originally discovered by scientists at Eli Lilly, which had discontinued its work on daptomycin as a drug candidate. Based on a breakthrough by Cubist scientists, Cubist resumed human trials with daptomycin in I.V. form, and the drug was approved by the FDA in 2003 as CUBICIN for the treatment of complicated skin and skin structure infections caused by certain gram-positive organisms. In 2006, the FDA approved an expanded U.S. label for CUBICIN for the treatment of S. aureus bloodstream infections (bacteremia), including right-sided infective endocarditis caused by MRSA and MSSA. The approval was based on results of the company's landmark Phase 3 trial studying the treatment of S. aureus bloodstream infections, including infective endocarditis. Today, we partner with other pharmaceutical companies to make CUBICIN available outside the United States in more than 70 countries, and the list continues to grow.

In December 2011, through its acquisition of Adolor Corporation, Cubist acquired rights to Adolor's commercialized product ENTEREG and its lead development candidate CB-5945, among other assets.

Click here for more information on Cubist's Pipeline.